HeartSciences Inc.: Business Overview, Financials & Competitive Analysis
HeartSciences Inc. scores 3/10 on the AskCyborg Cyborg Score (Weak). Speculative AI-driven medical device play with high revenue growth potential but substantial profitability and regulatory hurdles ahead. The company currently has negative EPS of -$6.88 with analyst forecasts predicting continued losses of -$3.80 for 2026. Despite forecast revenue growth of 488.3%, the company remains pre-profitability with minimal scale and faces.
What is HeartSciences Inc.'s industry? HeartSciences Inc. (heartsciences.com) operates in Medical Device / Healthcare Information Technology - AI-Enhanced Cardiac Diagnostics. AskCyborg classifies HeartSciences Inc. under Medical Device / Healthcare Information Technology - AI-Enhanced Cardiac Diagnostics in its company registry.
HeartSciences is an AI-powered medical technology company that applies artificial intelligence to electrocardiography (ECG) to expand clinical usefulness. The company develops AI-ECG solutions including the MyoVista w...
Cyborg Score thesis
Speculative AI-driven medical device play with high revenue growth potential but substantial profitability and regulatory hurdles...
Read the full analyst-debate transcript →Get the Latest HeartSciences Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeHeartSciences Inc. Overview
Pro stress-test →HeartSciences is an AI-powered medical technology company that applies artificial intelligence to electrocardiography (ECG) to expand clinical usefulness. The company develops AI-ECG solutions including the MyoVista wavECG device and MyoVista Insights cloud-based platform, targeting earlier cardiac disease detection in point-of-care clinical settings.
Strategic Profile
Pro stress-test →The company focuses on making ECG a more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. With a micro-cap valuation and early-stage commercial traction, HeartSciences is positioned as a pre-revenue growth play betting on AI-enhanced cardiac diagnostics adoption.
Competitive Landscape
Pro stress-test →HeartSciences operates in the AI-enhanced ECG/cardiac diagnostic space, competing with established medical device manufacturers (GE Healthcare, Philips, Medtronic) that have AI initiatives, as well as emerging cardiac AI startups. The company's differentiation rests on its specialized MyoVista platform and cloud-agnostic architecture, though commercial traction remains limited relative to incumbents.
Industry Context
HeartSciences Inc. operates in Medical Device / Healthcare Information Technology - AI-Enhanced Cardiac Diagnostics.
Key facts
Founded: 2007 · Headquarters: Southlake, Texas, US · Employees: 15 · Revenue: Minimal/Pre-commercial stage · Market cap: $8.91M